Core Insights - Climb Bio, Inc. has made significant progress in its clinical development programs for budoprutug and CLYM116, with multiple trials ongoing and initial data expected in 2026 [2][3][4] Group 1: Budoprutug Program - Budoprutug, an anti-CD19 monoclonal antibody, has initiated a Phase 2 trial in Primary Membranous Nephropathy (pMN) with first patient dosing achieved in November 2025 [4] - The Phase 1b/2a trial in Immune Thrombocytopenia (ITP) is ongoing, focusing on safety, tolerability, and preliminary efficacy [4] - A global Phase 1b trial in Systemic Lupus Erythematosus (SLE) is also underway, with regulatory clearance for a parallel trial in China received in December 2025 [4][11] - Budoprutug has shown long-term control of proteinuria in pMN patients, as presented at the 2025 ASN Kidney Week [4] Group 2: CLYM116 Program - CLYM116, an anti-APRIL monoclonal antibody, has initiated a Phase 1 study in healthy volunteers, with initial data expected in mid-2026 [8][11] - The antibody targets APRIL, a key driver of B-cell activity in autoimmune diseases, and employs a novel mechanism for enhanced efficacy [13] Group 3: Financial Position and Strategic Priorities - Climb Bio maintains a strong financial position, with cash runway expected to extend into 2028 [2][6] - The company has achieved 20 regulatory clearances for clinical trials and activated 45 trial sites globally, indicating robust clinical execution [3] - 2026 is anticipated to be a transformative year with multiple data readouts from ongoing trials, addressing unmet needs in renal and B-cell mediated diseases [3][4]
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026